MENU
FEB 22, 2023 Opens: 6:00 AM PST

Drug Discovery & Development Virtual Event Series 2023



Labroots and the Drug Discovery planning committee are pleased to announce its 6th annual event in the Drug Discovery & Development Virtual Event Series. Labroots will host this online-only event on February 22, 2023. The Drug Discovery planning committee will invite speakers from industry and academia to discuss key challenges, new opportunities, and recent successes in the current landscape of drug discovery and development.

The tracks and sub-topics for this year's event include:
  • Improved Models in Drug Discovery and Preclinical Development
    • Emerging Assays
    • Organoid Models
    • Predicting Safety and Efficacy
  • New Methods in PK/PD and Pharmacogenomics
    • PGX of GPCRs
    • In-vitro Models of Toxicity
  • Biomarker Applications in Clinical Development
    • Innovations in Biomarkers
    • Digital Solutions
    • Proteomics

Call for Posters — Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Plan now to have your poster included in the 2023 Drug Discovery & Development Virtual Event. Submission is free. Submit your abstract here.

Our virtual conference allows you to participate in a global setting with no travel or cost to you. The event will remain open for 2 years from the date of the live event, and the webinars will be available for unlimited on-demand viewing.  This virtual conference also offers increased reach for the global drug discovery community with a high degree of interaction through live-streaming video and chat sessions.

Continuing Education
Labroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this event, you can earn 1 Continuing Education credit per presentation for a maximum of 30 credits.

Use #LRdrug to follow the conversation!


Speaker
  • Per Venge, MD PhD

    Professor, Department of Medical Sciences, Clinical Chemistry, Uppsala University
    BIOGRAPHY

Show Resources

Agenda

  • The Many Diagnostic Potentials of Human Neutrophil Lipocalin (HNL)

    The Many Diagnostic Potentials of Human Neutrophil Lipocalin (HNL)

    Per Venge, MD PhD
    Professor, Department of Medical Sciences, Clinical Chemistry, Uppsala University
    BIOGRAPHY
  • Biomarker Applications in Clinical Development
  • The Many Diagnostic Potentials of Human Neutrophil Lipocalin (HNL)

    The Many Diagnostic Potentials of Human Neutrophil Lipocalin (HNL)

    Per Venge, MD PhD
    Professor, Department of Medical Sciences, Clinical Chemistry, Uppsala University
    BIOGRAPHY

Speakers


  • Per Venge, MD PhD
    Per Venge, MD PhD

    Professor, Department of Medical Sciences, Clinical Chemistry, Uppsala University

    BIOGRAPHY

Sponsored by

For information on becoming a sponsor or exhibitor, please click here.


Committee

To download the Program Committee brochure here.


  • Shaifali Bhalla, Ph.D.

    Dr. Shaifali Bhalla is Associate Professor of Pharmaceutical Sciences and Associate Dean of Administrative Affairs at Midwestern University College of Pharmacy, Downers Grove, IL. She received her Ph.D. from the University of Illinois at Chicago, USA in 2005. Dr. Bhalla's ...

    See more See less
  • Audrey Dubourg, MSc, PhD

    Audrey is an experienced researcher in microbiology, parasitology with significant experience in molecular biology and 3D mammalian cell culture. As Product Manager, she is responsible for CN Bio's PhysioMimix™ Organ-on-a-chip systems and their implementation in research ...

    See more See less
  • Matthew Flegal

    Matt entered the research field over 20 years ago as a lab animal technician at the TSI/Mason contract research facility. He has worked at both contract facilities such as TSI and OREAD Biosafety as well in industry at Pharmacia, Pfizer, and Sanofi-Aventis. During that period he ...

    See more See less
  • Martin Shaw

    Between 1994-2015 he worked at EKF Diagnostics in Wales (formerly Argutus Medical) where he introduced and promoted a wide range of novel kidney and liver tests, including important biomarkers that are now being evaluated by the IMI (Innovative Medicines Initiative) and FDA as ...

    See more See less
  • Matthew Shipton

    Over the past 16 years, Mr. Shipton has amassed deep domain expertise in cell-based products and services. Currently serving as President of Novabiosis, Inc. Mr. Shipton brings a skill for implementing sales-driven business strategies, an extensive track record of meeting and ...

    See more See less
Help

Demographics

Show Resources
Event Countdown
  • 0 Days
  • 0 Hours
  • 0 Minutes
  • 0 Seconds